TerminatedNot Applicable

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

Stopped: The study was stopped due to exhaustion of funding. No additional financial support could be obtained to continue study operations as planned.

United States303 participantsStarted 2022-08-26

Plain-language summary

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Provision of signed and dated informed consent form
. Stated willingness to comply with all study procedures and availability for the duration of the study
. Aged at least 18 years old at time of consent
. Diagnosed with AML, in complete remission
. Complete remission (CR) definition per local institutional criteria

Exclusion criteria

. MRD positivity is not an exclusion criterion

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Overall Survival

Timeframe: Through up to 3 years post-alloHCT

Cumulative incidence of relapse

Timeframe: Through up to 3 years post-alloHCT

Trial details

NCT IDNCT05224661

SponsorCenter for International Blood and Marrow Transplant Research

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2025-12-12

View on ClinicalTrials.gov More Acute Myeloid Leukemia in Remission trials